Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1002/em.2860090313 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
The kinetically-derived maximal dose (KMD) is defined as the maximum external dose at which kinetics are unchanged relative to lower doses, e.g., doses at which kinetic processes are not saturated.
View Article and Find Full Text PDFPlatinum as both a drug and its modulator - Do platinum nanoparticles influence cisplatin activity?
Chem Biol Interact
December 2024
Laboratory of Biophysics, University of Gdańsk, Gdańsk, Poland. Electronic address:
Breast cancer was the most frequent cause of cancer death in females in 2022. Despite the development of personalized therapies, chemotherapy frequently remains the only available treatment method. However, the administration of classic antineoplastic drugs, like cisplatin (CDDP), often causes severe side effects and may lead to drug resistance making the therapy inefficient.
View Article and Find Full Text PDFImpact of inhibitory KIR ligand mismatch and other variables on outcomes following myeloablative posttransplant cyclophosphamide-based T-cell-replete haploidentical bone marrow transplantation.
Front Immunol
December 2024
German Cancer Consortium (DKTK), Partner site Frankfurt/Mainz, a partnership between DKFZ and University Medical Center Frankfurt, Frankfurt, Germany.
Introduction: Posttransplant cyclophosphamide (PTCy) has revolutionized the landscape of human leukocyte antigen (HLA)-haploidentical hematopoietic cell transplantation (haplo-HCT), providing a pivotal therapeutic option for patients with hematological malignancies who lack an HLA-matched donor.
Methods: In this retrospective analysis involving 54 adult patients undergoing PTCy-based haplo-HCT, we evaluated the impact of inhibitory killer immunoglobulin-like receptor (KIR)/HLA mismatch, alongside patient, donor, and transplant factors, on clinical outcomes within a homogeneous cohort characterized by a myeloablative conditioning regimen and bone marrow graft.
Results: With a median follow-up of 73.
Integrative multi-omics analysis uncovers tumor-immune-gut axis influencing immunotherapy outcomes in ovarian cancer.
Nat Commun
December 2024
Department of Gynecologic Oncology, Roswell Park Comprehensive Cancer Center, Buffalo, NY, 14263, USA.
Article Synopsis
- Recurrent ovarian cancer patients, especially those resistant to platinum treatments, currently have few effective curative options, prompting a phase 2 clinical trial (NCT02853318) that combined pembrolizumab with bevacizumab and oral cyclophosphamide.
- The trial included 40 patients and showed promising results, with a median progression-free survival of 10.2 months, a 47.5% objective response rate, and 30% of patients achieving stable disease for over a year while maintaining a good quality of life.
- Comprehensive analysis revealed that increased T and B cell count and specific microbiome patterns correlated with strong clinical responses, suggesting that understanding the immune environment and gut microbiome could enhance future cancer treatment
Early assessment of antibodies decline in Chagas patients following treatment using a serological multiplex immunoassay.
Nat Commun
December 2024
InfYnity Biomarkers, Lyon, France.
Chagas disease following infection with Trypanosoma cruzi is a major public health issue, with the disease spreading beyond endemic regions and becoming more global due to the migration of infected individuals. The currently available anti-parasitic drugs, nifurtimox and benznidazole, remain insufficiently evaluated for their efficacy in adult patients. A key challenge is the lack of markers for parasitological cure, which also precludes the development of new treatments.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!